Artesunate and dihydroartemisinin (DHA): Unusual decomposition products formed under mild conditions and comments on the fitness of DHA as An Antimalarial Drug

ChemMedChem

Volumn 2, Issue 10, 2007, Pages 1448-1463

  Haynes, Richard K ^a   Chan, Ho Wai ^a   Lung, Chung Man ^a   Ng, A Chun ^a   Wong, Ho Ning ^a   Shek, Lai Yung ^a   Williams, Ian D ^a   Cartwright, Anthony ^b   Gomes, Melba F ^c  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b Pharmaceutical Regulatory Consultant   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Artemisinins; Artesunate; DHA; Malaria; Thermal instability

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; DIHYDROQUINGHAOSU; UNCLASSIFIED DRUG;

ARTICLE; CHEMISTRY; DIMERIZATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SUPPOSITORY;

ANTIMALARIALS; ARTEMISININS; DIMERIZATION; MAGNETIC RESONANCE SPECTROSCOPY; SUPPOSITORIES;

EID: 35848962653     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200700064     Document Type: Article

References (83)

1. J.-M Liu, M.-Y. Ni, J.-F. Fan, Y.-Y. Tu, Z.-H. Wu, Y.-L. Wu, W.-S, Zhou, Acta Chim. Sin. 1979, 37, 129-141.
2. Y. Li, P.-L. Yu, Y.-X. Chen, L. Q. Li, Y.-Z. Gai, D. S. Wang, Y.-P. Zheng, Ke Xue Tong Bao 1979, 24, 667-669;
3. X. Liu, Yao Xue Tong Bao 1980, 15, 183;
4. X. Liu, Faming Zhuanli Shenqing Gongkai Shuomingshu CN 85100781, 20 Aug, 1986 (Chem. Abstr. 1987, 107, 78111).
5. Y. Li, P.-L. Yu, Y.-X. Chen, L.-Q. Li, Y.-Z. Gai, D.-S. Wang, Y.-P. Zheng, Acta Chim. Sin. 1981, 16, 429-439.
6. Y. Li, P.-L. Yu, Y.-X. Chen, R.-Y. Ji, Acta Chim. Sin. 1982, 40, 557-561.
7. L. Li, Y.-C. Dong, N. J. Zhu, Jiegou Huaxue, 1986, 5, 73-77;
8. (Chem. Abstr. 1987, 107, 236 339).
9. X.-D. Luo, H. J. C. Yeh, A. Brossi, J. L. Flippen-Anderson, R. Gilardi, Helv. Chim. Acta 1984, 67, 1515-1522.
10. R. K. Haynes, H.-W. Chan, M. K. Cheung, W.-L. Lam, M. K. Soo, H. W. Tsang, A. Voerste, I. D. Williams, Eur. J. Org. Chem. 2002, 113-132.
11. R. K. Haynes, Curr. Med. Chem. 2006, 13, 509-537.
12. "Antimalaria Studies on Qinghaosu": Qinghaosu Antmalaria Coordinating Research Group, Chin. Med. J. 1979, 92, 811-816.
13. a) J.-B. Jiang, G.-Q. Li, X.-B. Guo, Y.-C. Kong, K. Arnold, Lancet 1982, 320, 285-288;
14. b) G.-Q. Li, K. Arnold, X. B. Guo, H. X. Jian, L. C. Fu, Lancet 1984, 324, 1360-1361.
15. a) P. L. Olliaro, W. R. Taylor, J. Postgrad. Med. 2004, 50, 40-44;
16. b) P. G. Kremsner, S. Krishna, Lancet 2004, 363, 284-296.
17. a) N. White, Philos. Trans. R. Soc. London Ser. B 1999, 354 739-749;
18. b) I. M. Hastings, W. M. Watkins, N. J. White, Philos. Trans. R. Soc. London Ser. B 2002, 357, 505-519;
19. c) M. Danis, F. Bricaire, Fundam. Clin. Pharmacol. 2003, 17, 155-160..
20. World Health Organization Guidelines for the Treatment of Malaria, WHO/HTM/MAL/2006, Ch. 7, pp. 16-27.
21. See: http://rbm.who.int/docs/mmss/procuringACTpreferentialprices.pdf.
22. P. N. Newton, M. van Vugt, P. Teja-Isavadharm, D. Siriyanonda, M. Rasameesoroj, P. Teerapong, R. Ruangveerayuth, T. Slight, F. Nosten, Y. Suputtamongkol, S. Looareesuwan, N. J. White, Antimicrob. Agents Chemother. 2002, 46, 1125-1127.
23. a) B. Pécoul, J.-R. Kiechel, "New Hope for Malaria Patients in 2006", Drugs for Neglected Diseases Initiative, Newsletter, January 2006, to be found under: http://www.researchappeal.org/dndi_pdf/ New_Hope_for_Malaria_Patients_06.pdf;
24. b) E. A. Ashley, K. M. Lwin, R. McGready, W. H. Simon, L. Phaiphun, S. Proux, N. Wangseang, W. Taylor, K. Stepniewska, W. Nawamaneerat, K. L. Thwai, M. Barends, W. Leowattana, P. Olliaro, P. Singhasivanon, N. J. White, F. Nosten, Trop. Med. Int. Health 2006, 11, 1653-1660.
25. W. Peters, B. L. Robinson, Ann. Trop. Med. Parasitol. 2000, 94, 23-35.
26. a) M. Adjuik, P. Agnamey, A. Babiker, S. Borrmann, P. Brasseur, M. Cisse, F. Cobelens, S. Diallo, J. F. Faucher, P. Garner, S. Gikunda, P. G. Kremsner, S. Krishna, B. Lell, M. Loolpapit, P. B. Matsiegui, M. A. Missinou, J. Mwanza, F. Ntoumi, P. Olliaro, O. Osimbo, P. Rezbach, E. Some, W. R. J. Taylor, Lancet 2002, 359, 1365-1372;
27. b) F. Abacassamo, S. Enosse, J. J. Aponte, F. X. Gomez-Olive, L. Quinto, S. Mabunda, A. Barreto, P. Magnussen, A. M. Ronn, R. Thompson, P. L. Alonso, Trop. Med. Int. Health 2004, 9, 200-208;
28. c) "Successful Partnership Brings Hope for Malaria", Drugs for Neglected Disease Initiative, 2007, to be found under: http://www.actwithasaq.org/en/asaq1.htm.
29. a) M. Takechi, M. Matsuo, C. Ziba, A. MacHeso, D. Butao, I. L. Zungu, I. Chakanika, M. D. Bustos, Trop. Med. Int. Health 2001, 6, 429-434;
30. b) S. Pincock, Br. Med. J. 2003, 327 360;
31. c) C. Schubert, Nature Medicine 2003, 9, 1097;
32. d) W. Peters, L. B. Stewart, B. L. Robinson, Ann. Trop. Med. Parasitol. 2005, 99, 457-472.
33. a) S. Looareesuwan, M. Imwong, P. Wilairatana, Lancet 2004, 363, 1838-1839;
34. b) S. Krudsood, M. Imwong, P. Wilairatana, S. Pukrittayakamee, A. Nonprasert, G. Snounou, N. J. White, S. Looareesuwan, Trans. R. Soc. Trop. Med. Hyg. 2005, 99, 142-149.
35. a) M. B. Denis, T. M. E. Davis, S. Hewitt, S. Incardona, K. Nimol, T. Fandeur, P. Thierry, Y. Poravuth, C. Lim, D. Socheat, Clin. Infect. Dis. 2002, 35, 1469-1476;
36. b) H. Karunajeewa, C. Lim, T. Y. Hung, K. F. Ilett, M. B. Denis, D. Socheat, T. M. E. Davis, Br. J. Clin. Pharmacol. 2004, 57, 93-99;
37. c) C. Karema, C. I. Fanello, C. van Overmeir, J.-P. van Geertruyden, W. van Doren, D. Ngamije, U. D'Alessandro, Trans. R. Soc. Trop. Med. Hyg. 2006, 100, 1105-1111.
38. a) T. M. E. Davis, T. Y. Hung, I. K. Sim, A. A. Karunajeewa, K. F. Ilett, Drugs 2005, 65, 75-87;
39. b) J. Tarning, Y. Bergqvist, N. P. Day, J. Bergquist, B. Arvidsson, N. J. White, M. Ashton, N. Lindegaardh, Drug Metab. Dispos. 2006, 34, 2011-2019.
40. Medicines for Malaria Venture, Geneva: "Dihydroartemisinin and piperaquine could become a major weapon against malaria", MMV02/1020, to be found under: http://www.mmv.org/article.php3?id_article=52.
41. a) G.-Q. Li, personal communication;
42. b) T. N. Trung, D. V. Phuc, "Comparison of Artequick Tablets and Granules in Treatment of Complicated Falciparum Malaria in Vietnam", proceedings of the Second International Artemisinin Compounds Workshop on the Evaluation of Clinical Studies, January 16-17, 2007, Guangzhou (China).
43. a) M. I. Awad, A. M. Alkadru, R. H. Behrens, O. Z. Baraka, I. B. Eltayeb. Am. J. Trop. Med. Hyg. 2003, 68, 153-158;
44. b) H. A. Karunajeewa, K. F. Ilett, K. Dufall, A. Kemiki, M. Bockarie, M. P. Alpers, P. H. Barrett, P. Vicini, T. M. E. Davis, Antimicrob. Agents Chemother. 2004, 48, 2966-2972;
45. c) J. A. Simpson, T. Agbenyega, K. I. Barnes, G. Di Perri, P. Folb, M. Gomes, S. Krishna, S. Krudsood, S. Looareesuwan, S. Mansor, H. McIlleron, R. Miller, M. Molyneux, J. Mwenechanya, V. Navaratnam, F. Nosten, P. Olliaro, L Pang, I. Ribeiro, M. Tembo, M. van Vugt, S. Ward, K. Weerasuriya, K. Win, N. J. White, PLoS Med. 2006, 3, 2113-2123.
46. a) Cooperative Research Group on Qinghaosu. A novel type of sesquiterpene lactone - qinghaosu, Kuo Xue Tong Bao 1977, 22, 142;
47. b) Qinghaosu Antimalaria Coordinating Research Group. Antimalaria studies on qinghaosu, Chin. Med. J. 1979, 92, 811-816;
48. c) Qinghaosu Research Group, Institute of Biophysics, Academia Sinica. Crystal structure and absolute configuration of qinghaosu, Scientia Sinica 1980, 23, 380-396;
49. D. Klayman, Science 1985, 228, 1049-1055.
50. X. D. Luo, C. C. Shen, Med. Res. Rev. 1987, 7, 29-52.
51. a) European Medicines Agency EMEA, August 2003, CPMP/ICH/2736/99 ICH Topic Q1A (R2) Stability Testing of New Drug Substances and Products; see: http://www.emea.europa.eu/pdfs/human/ich/273699en.pdf; b) European Medicines Agency EMEA, June 2006, CPMP/ICH/2738/99 ICH Topic Q3B (R2) Impurities in New Drug Products, Step 5, Note for Guidance on Impurities in New Drug Products.
52. European Medicines Agency, June 2006, CPMP/ICH/421/02 ICH Topic Q1F, Stability Data Package for Registration Applications in Climatic Zones III and IV.
53. a) "Stability Testing of Pharmaceutical Products in a Global Environment": S. Kopp, Regulatory Affairs Journal Pharma 2006, 291-284, to be found under: http://www.rajpharma.com;
54. b) WHO Technical Report Series No. 863, Annex 5; Report of the 37th meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, Geneva, October 2001, 22-26.
55. Y. Jackson, F. Chappuis, L. Loutan, W. Taylor, Malar. J 2006, 5, 81, to be found under: http://www.malariajournal.com/ content/5/1/81.
56. M. A. Atemnkeng, K. De Cock, J. Plaizier-Vercammen, Trop. Med. Int. Health 2007, 12, 68-74.
57. A. J. Lin, A. D. Theoharides, D. L. Klayman, Tetrahedron 1986, 42, 2181-2184.
58. J. K. Baker, J. D. McChesney, H.-T. Chi, Pharm. Res. 1993, 10, 662-666.
59. E. L. Clennan, C. S. Foote in Organic Peroxides (Ed.: W. Ando), Wiley, New York, 1992, Ch. 5, p. 309, and references therein.
60. R. K. Haynes, H.-O. Pai, A. Voerste, Tetrahedron Lett. 1999, 40, 4715-4718.
61. a) J. D. Berman, J. H. Stanley, W. V. Sherman, S. G. Cohen, J. Am. Chem. Soc. 1963, 85, 4010-4013;
62. b) D. E. Applequist, L. Kaplan, J. Am. Chem. Soc. 1965, 87, 2195-2200;
63. c) K. Maruyama, M. Taniuchi, S. Oka, Bull. Chem. Soc. Jpn. 1974, 47, 712-714;
64. d) J. W. Wilt, L. L. Maravetz, J. F. Zawadzki, J. Org. Chem. 1966, 31, 3018-3025.
65. W.-M. Wu, Y-K. Wu, Y.-L. Wu, Z.-J. Yao, C. M. Zhou, Y. Li, F. Shan, J. Am. Chem. Soc. 1998, 120, 3316-3325.
66. R. K. Haynes, M. K. S. Probert, I. D. Wilmot, Aust. J. Chem. 1978, 31, 1737-1745.
67. L. F. R. Cafferata, R. Jeandupeux, G. P. Romanelli, C. M. Mateo, C. W. Jefford, Afinidad 2003, 60 206-211.
68. R. K. Haynes, W.-Y. Ho, H.-W. Chan, B. Fugmann, J. Stetter, S. L. Croft, L. Vivas, W. Peters, B. L. Robinson, Angew. Chem. 2004, 116, 1405-1409;
69. Angew. Chem. Int. Ed. 2004, 43, 1381-1385.
70. K. T. Batty, K. F. Ilett, T. Davis, T. M. E. Davis, J. Pharm. Pharmacol. 1996, 48, 22-26.
71. A. Brossi, B. Venugopalan, L. Dominguez Gerpe, H. J. C. Yeh, J. L. Flippen-Anderson, P. Buchs, X.-D. Luo, W. Milhous, W. Peters, J. Med. Chem. 1988, 31, 645-650.
72. R. K. Haynes, H. W. Chan, W.-Y. Ho, C. K.-F. Ko, L. Gerena, D. E. Kyle, W. Peters, B. L. Robinson, ChemBioChem 2005, 6, 659-667.
73. J. K. Baker, H. T. Chi, Heterocycles 1994, 38, 1497-1505.
74. L.-K. Sy, S.-M. Hui, K.-K. Cheung, G. D. Brown, Tetrahedron 1997, 53, 7493-7500.
75. B. Yagen, Y. M. Pu, H. J. Yeh, H. Ziffer, J. Chem. Soc. Perkin Trans. 1 1994, 843-846.
76. P. M. O'Neill, G. H. Posner, J. Med. Chem. 2004, 47, 2945-2964.
77. R. K. Haynes, H.-N. Wong, N.-C. Ng, C. M. Lung, H. W. Chan, "Identification and Assessment of Artesunate Degradants in Rectal Artesunate Capsules", Special Programme for Research & Training in Tropical Diseases, World Health Organization, Geneva 27, Switzerland, July 2006.
78. W. Li, W.-K. Mo, D. Shen, L.-B. Sun, J. Wang, S. Lu, J. M. Gitschier, B. Zhou, PLoS Genet. 2005, 1, 329-334.
79. S. Arbe-Barnes. "Pyronaridine Artesunate Combination: Phase I Clinical and Pharmacokinetic Study Results; Pyronaridine Artesunate" FCT MIM Malaria Conference, Medicines for Malaria Venture, Geneva, 2005.
80. K. T. Batty, K. F. Ilett, S. M. Powell, J. Martin, T. M. E. Davis, Am. J. Trop. Med. Hyg. 2002, 66, 130-136.
81. T. Q. Binh, K. F. Ilett, K. T. Batty, T. M. E. Davis, N. C. Hung, S. M. Powell, L. T. A. Thu, H. V. Thien, H. L. Phuöng, V. D. B. Phuong, J. Clin. Pharmacol., 2001, 51, 541-546.
82. World Health Organization Media Centre: Quality and Safety of Vaccines from Development to Delivery Fact Sheet No. 295, November 2005, to be found under: http://www.who.int/mediacentre/factsheets/fs295/en/index.html.
83. China Cooperative Research Group on Qinghaosu and its Derivatives as Antimalarials, J. Tradit. Chin. Med. 1982, 2, 9-16.